#$%^&*AU2012321106A120130523.pdf#####Atty. Docket No.: 08047.0057-00000 ABSTRACT OF THE DISCLOSURE The present disclosure relates to methods for the treatment of cancer in patients in recognized need of such treatment. The methods comprise administering to such a patient an NAE inhibitor or a pharmaceutically acceptable salt thereof, such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methy sulfamate (MLN4924) or {(15,25,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]aminolpyrimidin-4-yl)oxy]-2hydroxycyclopentyl}methyl sulfamate (1-216), and a hypomethylating agent or a pharmaceutically acceptable salt thereof, such as azacitidine or decitabine. Also disclosed are medicaments for use in the treatment of cancer. 35
